Skip to content
PeptideHormone

Finished sooner

Cagrilintide gets talked about as a stronger GLP-1. It is a different signal. Amylin ends a meal; GLP-1 turns down the wanting of one, and the two live in neighboring circuits, one of which is also the nausea center. On its own, in a 26-week phase 2 trial, once-weekly cagrilintide took off a mean 10.8% of body weight at the top dose — a little past liraglutide, with nausea in up to 47% and discontinuations no worse than placebo. The number people quote, −20.4% at 68 weeks, is CagriSema, the combination with semaglutide, and in that trial gastrointestinal events reached 79.6%. What the experience is likely to be, which result belongs to which vial, and the expectations an approved label would have set if one existed. Investigational. Bullish on the science, sceptical on the page.

11 min read · reviewed November 2026

The model people bring with them

Cagrilintide shows up, in conversation, as the thing you add when a GLP-1 was not enough. The nickname is short, the reputation is that it is “strong,” and the number attached to it is usually the one from the combination trial. That packaging is why it has not traveled the way semaglutide did. A drug becomes ordinary when a lot of people can stay on it and still recognize their week. Cagrilintide is ordinary in neither sense: it is investigational, and the experience it produces is a poor match for the GLP-1 story people use to explain it.

Semaglutide’s cultural explanation is “the noise stopped.” Food is still food; it just asks for less of your attention. That account is informal, and it is also why the drug scaled. Friends could warn each other about nausea in the first weeks and then describe a life that was smaller at the plate and otherwise intact. Cagrilintide does not have that shared script. The only approved amylin drug, pramlintide, is a mealtime injection paired with insulin, known mostly to endocrinology clinics. A prospective user of the weekly analog is usually meeting the hormone for the first time, through a second vial, with the first drug’s expectations still in place.

The mismatch

If the hope is “semaglutide, but more of it,” cagrilintide is the wrong sentence. It is a second satiety system. More brake is not the same feeling as a stronger version of the first brake.

Two kinds of less hungry

Amylin is released with insulin, in the same granule, as the meal is being absorbed. Its job is to say that this meal has gone on long enough: slow the stomach, shrink the next bites, and let the hindbrain close the meal. In animals the signature is specific. They begin eating at a normal rate and stop sooner. The meal is truncated. It is not that the food became uninteresting before they sat down.

GLP-1’s satiety is a wider net — gut, pancreas, and reward circuits — and the part people notice is often earlier than the last bite. Less looking forward to the meal, less finishing it out of habit, sometimes an active disinterest. Both hormones reduce intake. They reduce different moments of it. Someone whose GLP-1 experience was “I forgot to eat lunch” can experience an amylin analog as “I sat down hungry and was done after a few bites, with the rest of the plate still looking like food.” That second feeling is closer to physical completion than to a changed appetite, and it collides harder with dinners that are social, slow, or the main pleasure of the day.

Pramlintide is the one place this physiology has a label. It is given at meals, on purpose: the signal arrives when the meal does, and it wears off. Cagrilintide is built to be present all week. The off switch is no longer timed to sitting down. Fullness, slowed emptying, and whatever nausea comes with them are a background, not a post-injection hour. That is the design. It is also the part no patient leaflet currently explains, because there is no label. Reference

Satiety and nausea are neighbors

Amylin is read in the area postrema, a hindbrain site with a thin blood–brain barrier so that a circulating hormone can be heard. The same neighborhood is the chemoreceptor trigger zone: the place the body uses to decide that something in the blood should be vomited. Satiety and nausea are not a clean effect plus an unfortunate side effect. They are adjacent uses of one sensory organ. Turning the meal-ending signal up moves you toward the border where “I have had enough” becomes “I feel sick.”

Cagrilintide is a dual agonist. It activates amylin receptors and the calcitonin receptor they are built from. Eloralintide was later engineered to prefer the amylin receptor, and in rats it produced less conditioned taste aversion than cagrilintide. That comparison is preclinical, in a different species, and it has never been repeated head-to-head in people (the selectivity piece). It is still the right warning for expectations. The weekly amylin analog already in late-stage trials was not designed to be the gentle one. A harsher stop, when it happens, is consistent with how the molecule was built. It is not proof that a given week of nausea means the dose was wrong. Preclinical

The phase 2 record matches the anatomy without dramatizing it. Gastrointestinal events — nausea, constipation, diarrhea — were the common adverse events, and they rose with dose: 41% to 63% on cagrilintide 0.3–4.5 mg, against 32% on placebo. Nausea specifically was 20% to 47%, against 18% (Lau et al., Lancet 2021). The paper’s own word for the program was that treatment “was well tolerated.” Permanent discontinuation for adverse events was about 4%, and it did not cluster in the cagrilintide arms. Both sentences are true. Nausea in nearly half of people at the top dose can still leave most of them in the trial. “Well tolerated” in a protocol is a completion statistic. It is not a promise that meals will feel the way they felt before. Clinical

Which number is the drug

At 26 weeks, mean weight loss on cagrilintide alone ran from 6.0% at the lowest dose to 10.8% at 4.5 mg once weekly, against 3.0% on placebo and 9.0% on liraglutide 3.0 mg daily. The 4.5 mg comparison with liraglutide was an estimated 1.8 percentage points (p = 0.03), on the trial-product estimand, which models what happened if people stayed adherent. The treatment-policy estimand, which keeps everyone who was randomized, landed in the same place. About a hundred people sat in each dose group. This is a real phase 2 result. It is also roughly the liraglutide neighborhood, not the poster on the group chat.

What was givenTrialMean weightThe part you feel
Cagrilintide alone, 0.3–4.5 mgPhase 2, 26 weeks−6.0% to −10.8%GI events 41–63%; nausea 20–47%
Liraglutide 3.0 mgSame trial−9.0%Active control, not a GLP-1 of the current generation
PlaceboSame trial−3.0%GI events 32%; nausea 18%
Cagrilintide 2.4 + semaglutide 2.4REDEFINE-1, 68 weeks−20.4%GI events 79.6%
PlaceboREDEFINE-1−3.0%GI events 39.9%
Phase 2 weight figures are the trial-product estimand (Lau et al., Lancet 2021); the treatment-policy estimand was similar. REDEFINE-1 weight figures are the treatment-policy estimand (Garvey et al., NEJM 2025). The combination row is not a forecast for cagrilintide alone. Registries: NCT03856047, NCT05567796.

The poster is REDEFINE-1. Adults with overweight or obesity, no diabetes, 68 weeks, lifestyle intervention in every arm: cagrilintide 2.4 mg coadministered with semaglutide 2.4 mg produced a mean −20.4% change in body weight, against −3.0% on placebo (treatment-policy estimand, the intention-to-treat number). Gastrointestinal adverse events affected 79.6% of the combination group and 39.9% of placebo, described as mainly transient and mild to moderate. The abstract’s conclusion is about the combination. It does not report the monotherapy arms’ percentages in the summary most people will read, which is how a two-drug result became the folk dose-response of one of the drugs.

Read the vial you have

−20.4% is two mechanisms at 68 weeks. 10.8% is cagrilintide alone at 26 weeks, at a higher monotherapy dose than REDEFINE used. Quoting the first as the expectation for the second is how people decide the drug “isn’t working” or, from the other direction, decide they should push it until the combination number appears from one pen.

What changes when it is stacked

The life-changing part, beyond GLP-1, is real, and it is narrower than the marketing sentence. On top of semaglutide, cagrilintide is a second independent brake on the same behavior. REDEFINE exists because the brakes add: the combination beat placebo by 17.3 percentage points, and the program was built with a semaglutide arm and a cagrilintide arm precisely so that addition could be seen. Addition on the scale is also addition in the stomach. Both drugs slow gastric emptying. A person who has already rearranged breakfast around semaglutide is not adding a subtle extra. They are asking a gut that empties late to empty later.

That is the practical reason it lacks mass appeal. Semaglutide’s tolerable plateau is wide enough that primary care can titrate toward it and a majority of trial participants can stay. The combination’s gastrointestinal line — four in five — says the plateau is narrower. Workdays, training, childcare, and restaurants all assume you can eat and drink on a schedule. A drug that ends meals early and holds food in the stomach rewrites that schedule. Some people experience the rewrite as the first time in years they are not thinking about food, and they will trade a lot for it. Others experience it as the removal of a daily pleasure plus a low-grade illness. The trials did not score those as separate outcomes. They scored nausea, vomiting, constipation, diarrhea, and abdominal pain, and they scored who left.

  • Early fullness. The effect to expect is a meal that finishes itself: normal hunger at the start, a hard stop partway through, leftovers that do not become a snack an hour later. That is the amylin phenotype, not a quoted percentage from a diary study.
  • Food sitting. Slowed gastric emptying is the mechanism, not a rare reaction. Large meals, high fat, and alcohol meet a stomach that is still working on the last one. On top of a GLP-1, this is the interaction, not a coincidence.
  • Nausea as a neighbor. In phase 2, nausea tracked the dose and still left discontinuation rates similar to placebo. Feeling sick during titration is common in the class. Being unable to keep fluids down is a different event — dehydration is the risk the symptom is pointing at, and it is a reason to stop and get care, not a sign the drug is “working.”
  • A smaller social life at the table. The unmeasured change is participation. Long dinners, cooking as a hobby, and eating because everyone else is eating get harder when satiety is a physical stop. GLP-1 often softens interest and leaves the occasion intact. Amylin is more likely to end the occasion.
  • The weight number you were promised. Alone, think of the phase 2 range — about 6% to 11% at 26 weeks — not the combination’s 20% at 68 weeks. Either figure is a mean. It describes a group, after a protocolized escalation, with lifestyle support. It does not describe a month on an uncounted product.

What is still unknown

No trial has asked people to describe the quality of their appetite on cagrilintide versus semaglutide in the same week. The food-noise account and the meal-termination account are the best readings of the biology and of how patients talk about the two classes. They are not endpoints. Fatigue, which became impossible to ignore in eloralintide’s phase 2, is not the lead finding of cagrilintide’s phase 2 abstract; absence from an abstract is not a demonstration that energy is spared. Taste aversion differs in rats and has not been compared in people.

There is also no decade of ordinary use to borrow expectations from. Pramlintide is meal-timed and tied to insulin. Cagrilintide is weekly, albumin-bound, and still in front of regulators as half of a combination. Anyone using it outside a trial is outside the population those percentages were measured in: no protocol visit, no guaranteed identity or purity of the vial, no one adjusting a co-prescribed GLP-1 because the stomach slowed further. The trial can tell you the shape of the experience. It cannot underwrite the product in front of you.

The orientation is short on purpose. Cagrilintide is highly active in the only way that matters for a first month: it pulls a brake most people have never felt as its own sensation, and it pulls harder when a GLP-1 is already pulled. The weight loss on its own is in a range an older GLP-1 already reached. The reason to understand it is the feeling, which is specific, physical, and easy to misread as a broken version of a drug you already know.

Common questions

Does cagrilintide feel like a GLP-1?
The overlap is that both reduce how much people eat and both commonly cause nausea. The difference is the kind of less. GLP-1 receptor agonists such as semaglutide are widely experienced as less interest in food — the “food noise” story. Amylin, which cagrilintide mimics, is a meal-termination signal: eating starts and then stops early, with the stomach emptying more slowly. Those are neighboring hindbrain circuits, and the amylin one sits in the area postrema, which is also where nausea and vomiting are triggered. A person who liked semaglutide because meals stayed pleasant and just got smaller can find cagrilintide’s stop abrupt. That contrast is mechanism plus the adverse-event pattern in trials. Nobody has published a head-to-head study of the subjective experience.
How much weight did cagrilintide lose on its own?
In the 26-week phase 2 trial (Lau et al., Lancet 2021; 706 adults with overweight or obesity, no diabetes), once-weekly cagrilintide reduced body weight by a mean 6.0% to 10.8% across 0.3–4.5 mg, against 3.0% on placebo and 9.0% on liraglutide 3.0 mg. The 4.5 mg result, 10.8%, was the trial-product estimand — the estimate that assumes people stayed on treatment. Gastrointestinal events ran 41–63% versus 32% on placebo, mostly nausea (20–47% versus 18%). About 4% stopped for adverse events, similar across groups. The −20.4% figure at 68 weeks is not this trial. It is CagriSema, cagrilintide 2.4 mg given with semaglutide 2.4 mg, in REDEFINE-1.
Why do people say cagrilintide is harder to live with than a GLP-1?
Because the number everyone repeats is the combination, and the combination’s side-effect line is steeper. In REDEFINE-1, gastrointestinal adverse events affected 79.6% of people on cagrilintide plus semaglutide and 39.9% on placebo — nausea, vomiting, diarrhea, constipation, or abdominal pain, mostly mild to moderate and transient, in the investigators’ summary. Two drugs that both slow the stomach are not a slightly stronger version of one of them. Cagrilintide alone, in phase 2, was described as well tolerated. The reputation for being “too active” usually arrives when someone stacks it on a GLP-1 they already find effective, and then meets a second brake.
Is cagrilintide approved?
No. Cagrilintide is investigational, alone and as the cagrilintide half of CagriSema. Novo Nordisk submitted the combination to the FDA in December 2025; no decision had been announced when this page was reviewed. The only amylin drug with a U.S. label is pramlintide (Symlin, 2005), a mealtime injection used with insulin. There is no patient leaflet that tells a prospective user what a week of cagrilintide is supposed to feel like. This page is that missing orientation, from the public trial record. It is not a dosing guide and not medical advice.

Educational reference on mechanism and published trial results, summarized from the public record. Doses appear only as the doses those trials studied, so the monotherapy result is not confused with the combination. Not a dosing guide, not medical advice, and not an endorsement of any use. Someone who cannot keep fluids down, or who is using insulin or a GLP-1 and becomes acutely ill, needs a clinician. Investigational, not approved: cagrilintide and CagriSema. Approved in the United States: pramlintide and semaglutide. Status checked November 2026.